Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?

Hims & Hers Health Inc HIMS shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own versions of blockbuster weight loss drugs.

What Happened: The FDA on Friday said in a court filing that it would allow drug compounders to continue offering compounded drugs while the agency reviews whether or not there is a shortage of the active ingredient used in Eli Lilly And Co’s LLY weight loss and diabetes drugs, per Reuters.

The decision came in response to a lawsuit by compounding industry group Outsourcing Facilities Association related to the FDA’s recent decision to remove tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, from its shortage list. Mounjaro had been on the regulator's shortage list since late 2022, and Zepbound had been on the list since April.

Hims & Hers Health sells cheaper versions of the aforementioned drugs, known as compounded drugs. Regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. Hims & Hers Health shares surged in May after the company said it would begin selling compounded versions of GLP-1 injections.

The Outsourcing Facilities Association reportedly put its lawsuit on hold after the FDA on Friday said it would reconsider its decision. The group claimed in its lawsuit that the FDA removed tirzepatide from its shortage list despite it remaining in short supply.

The limited supply for weight-loss and diabetes drugs from Lilly and rival Novo Nordisk A/S NVO have sparked a demand boom for compounded drugs. Semaglutide, the active ingredient in Novo Nordisk’s drugs, remained on the FDA’s shortage list as of Monday.

See Also: More Patients On Eli Lilly’s Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson’s Drug

HIMS Price Action: Hims & Hers Health shares were up 6.6% at $19.94 at the time of publication, according to Benzinga Pro.

Photo: Shutterstock.